After PCI in AF, DAT for 1 mo was noninferior to 12 mo for mortality or thromboembolic events and reduced major or nonmajor bleeding.

After PCI in patients with atrial fibrillation, 1 month of DAT is noninferior to 12 months for mortality or thromboembolic events and reduces major or nonmajor bleeding.

• Why it matters: Longer dual antithrombotic therapy after PCI may increase bleeding risk, but the optimal duration for atrial fibrillation patients is unclear.
• What they did: In a post-PCI atrial fibrillation population, investigators compared dual antithrombotic therapy given for 1 month versus 12 months, assessing mortality and thromboembolic events and bleeding outcomes.
• The result: The shorter 1-month strategy was noninferior for mortality or thromboembolic events and was linked to less major or nonmajor bleeding, supporting shorter-duration DAT after PCI.

AI summary of the abstract · may contain errors · not medical advice · read the paper.